Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Clovis Oncology Inc. Stock

Price
 
€8.34
0.068
0.850%
Target price
€12.00
23.01.20 / Tradegate WKN: A1JPJY / Symbol: CLVS / Name: Clovis Oncology / Stock / Biotechnologie & medizinische Forschung
Latest predictions
€12.00
18.01.20
buy
€8.00
14.01.20
buy
€30.00
13.01.20
buy
€10.00
12.01.20
buy
-
09.12.19
buy
-
25.11.19
buy
Your prediction

Clovis Oncology Inc. Stock

The Clovis Oncology Inc. stock is trending slightly upwards today, with an increase of €0.068 (0.850%) compared to yesterday's price.
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Clovis Oncology Inc..
As a result the target price of €12.00 shows a positive potential of 43.971% compared to the current price of €8.34 for Clovis Oncology Inc..
Register To Post

Other discussions about Clovis Oncology Inc. Stock

New thread

News

Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib)

Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019


Clovis
Oncology
, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial

Clovis Oncology Announces Debt Refinancing Transaction


Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the

Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium


Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for

Clovis Oncology Announces Third Quarter 2019 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and